Coronavirus disease (COVID-19) updates

Novartis commits to donating up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Friday, 20 mars 2020 - 4:23am

Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials.

  • Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
  • Novartis Sandoz division will pursue appropriate regulatory authorizations and, upon approval, will work with stakeholders to determine how best to get this medicine to the patients who need it
  • Commitment builds on recently announced USD 20 million Novartis COVID-19 Response Fund, drug discovery and development collaborations and essential medicines price stability
  • Novartis encourages industry, governments and international institutions to work together to ensure adequate global access of medications to treat COVID-19 patients

Read the full media release

Novartis COVID-19 Information Centre

 

Liens associés